The article by Yang, et al, entitled, "Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia" (doi: 10.1200/JCO.2014.59.4671), was published online January 26, 2015, with errors.
In the Results section, the third sentence of the third paragraph described patients with the CT genotype, whereas it should have been the TC genotype, as follows:
"Only one patient was homozygous for the variant allele (CC genotype) at TPMT SNP rs1142345, and this individual was highly sensitive to MP, with a dose intensity of only 6%, compared with patients with the TC genotype (n = 39) or wild-type TT genotype (n = 617), who tolerated an average dose intensity of 65.7% (standard deviation [SD], ± 27.7%) and 83.5% (SD, ± 22.5%), respectively."
Figure 2C was labeled as "NUDT15 rs166855232" whereas it should have been "NUDT15 rs116855232."
In Figure 3D, the x-axis labels were inadvertently reversed; the labels were given as TC (n = 204) and CC (n = 1), whereas they should have been CC (n = 204) and TC (n = 1).
In the Results section, the fourth sentence of the last paragraph gave the number of patients with heterozygous genotype for only one of the two genes as 27, whereas it should have been 67, as follows:
"Interestingly, patients heterozygous for both TPMT and NUDT15 risk variants (n = 4) also had substantially lower dose intensity compared with those with heterozygous genotype for only one of the two genes (n = 67; P = .018)."
In the Discussion section, the ninth sentence of the first paragraph and the fifth sentence of the last paragraph misidentified "rs166855232," which should have been "rs116855232" in both places.
These have been corrected as of February 9, 2015. The authors apologize for the mistakes.
Additionally, in the Abstract, the fourth sentence of the Results sections indicated the NUDT15 variant was monomorphic in Africans, whereas it should have been "not observed," as follows: "The NUDT15 variant was most common in East Asians and Hispanics, rare in Europeans, and not observed in Africans, contributing to ancestry-related differences in MP tolerance."
In the Results section, the third sentence of the fifth paragraph indicated the risk allele was monomorphic in Africans, whereas it should have been "not observed," as follows: "It was exceedingly rare in Europeans (0.2%) and not observed in Africans (Fig 3A)."
In the footnotes for Table 1, the note following the asterisk (*) gave the TPMT variation incorrectly as TPTM, and should have read: "In model three, for each additional T allele at rs116855232, mean MP dose intensity is estimated to decrease 22 percentage points while holding ancestry factors and TPMT variation at any fixed levels."
These have been corrected as of March 2, 2015. The authors apologize for the mistakes.